Neurocritical Care News

For infants with Down syndrome, early intervention to address obstructive sleep apnea may lead to better cognitive and behavioral outcomes at 36 months, according to new research from The Lancet.

An Alabama-based company announced that the FDA has granted 510(k) clearance to its cyber device and AI system, which are designed to improve efficiency and accuracy of glioblastoma care.

A Maryland-based neurotechnology company has secured a U.S. patent for its novel prosthetic translucent, cranial implant intended for use during neurosurgical procedures.

The FDA has granted 510(k) clearance to a plant-based, hemostatic gel to treat moderate to severe bleeding, according to the manufacturer.

The FDA has granted rare pediatric disease designation to an investigational oligonucleotide for the treatment of boys with Duchenne muscular dystrophy who are amenable to exon 53 skipping, according to the manufacturer.

The Healio news staff received an APEX award in the category of Writing/Topics for work on the potential role of psychedelics and alternative therapies for mental health issues and other medical conditions.

In young male American football players, concussion symptoms and severity were higher for those who sustained the injury on natural grass compared with artificial turf, according to new research in the Clinical Journal of Sports Medicine.

The FDA has granted Regenerative Medicine Advanced Therapy designation to an autologous, fully human CD19 chimeric antigen receptor T-cell therapy candidate, to treat those with progressive myasthenia gravis.

The FDA has approved Medtronic’s Asleep Deep Brain Stimulation surgery for individuals diagnosed with Parkinson’s disease as well as those with essential tremor, according to the manufacturer.

Bypassing the blood-brain barrier remains an obstacle for novel therapeutics. Healio spoke to Thomas Chen, MD, PhD, founder and CEO of NeOnc, to find out how a novel nasal spray formulation to treat brain cancer overcomes these challenges.